505 Parnassus Avenue, Room M1083, Box 0111, San Francisco, CA 94117, USA.
Mayo Clinic, Gonda 18 South, Rochester, MN 55905, USA.
Clin Chest Med. 2021 Jun;42(2):287-294. doi: 10.1016/j.ccm.2021.03.006.
We are in the midst of transformative innovation in health care delivery and clinical trials in idiopathic pulmonary fibrosis (IPF). Health systems are uniquely positioned at the crossroad of these shifting paradigms, equipped with the resources to expand the research pipeline in IPF through visionary leadership and targeted investments. The authors hope that by prioritizing development of health information technology, supporting a broader range of clinical trial designs, and cultivating broad stakeholder engagement, health systems will generate data to address knowledge-evidence-practice gaps in IPF. This will continue to improve the ability to deliver high-quality, safe, and effective care.
我们正处于特发性肺纤维化 (IPF) 医疗服务和临床试验的变革性创新之中。医疗系统处于这些转变范式的交汇点，拥有通过有远见的领导和有针对性的投资来扩大 IPF 研究管道的资源。作者希望通过优先开发健康信息技术、支持更广泛的临床试验设计以及培养广泛的利益相关者参与，医疗系统将生成数据来解决 IPF 中的知识-证据-实践差距。这将继续提高提供高质量、安全和有效的护理的能力。
